Please provide your email address to receive an email when new articles are posted on . W.L. Gore and Associates announced its occluder device was approved by the FDA for percutaneous closure of ...

Gore ASSURED Clinical Study results through 36 months demonstrate 100 percent closure success * with the GORE ® CARDIOFORM ASD Occluder, and consistent safety outcomes † across a broad range of ASD ...

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) has completed enrollment for the pivotal phase of the Gore ASSURED Clinical Study. This investigational device exemption (IDE) ...

FLAGSTAFF, Ariz.--W. L. Gore & Associates today reported the first patient enrolled in the GORE® Septal Occluder Clinical Study evaluating the safety and efficacy of the new GORE Septal Occluder in ...

May 31, 2007 (Seattle, WA) - The pivotal trial of a new device approved for the percutaneous closure of atrial septal defects (ASD)--the HELEX septal occluder (WL Gore and Associates, Flagstaff, ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

W.L. Gore now has final U.S. regulatory approval to add a second product to an ongoing 700-patient pivotal clinical trial exploring whether its devices designed to close a hole in the heart help ...